StockData
AstraZeneca PLC logo

AstraZeneca PLC (AZN) stock

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

AstraZeneca's revenue for the twelve months ending Jun 30, 2021 was $29.01B, up 16.2% year over year. For fiscal 2025 it was $58.74B, up 8.6% from the year before. Over ten years it grew 9.0% a year on average. The highest annual figure on record is $58.74B in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$58.74B+8.6%
FY2024Dec 31, 2024$54.07B+18.0%
FY2023Dec 31, 2023$45.81B+3.3%
FY2022Dec 31, 2022$44.35B+18.5%
FY2021Dec 31, 2021$37.42B+40.6%
FY2020Dec 31, 2020$26.62B+9.2%
FY2019Dec 31, 2019$24.38B+10.4%
FY2018Dec 31, 2018$22.09B-1.7%
FY2017Dec 31, 2017$22.47B-2.3%
FY2016Dec 31, 2016$23.00B-6.9%
FY2015Dec 31, 2015$24.71B–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$15.38B+42.8%
Q2 FY2025Jun 30, 2025$14.46B+75.9%
Q2 FY2024Jun 30, 2024$12.94B+78.3%
Q2 FY2023Jun 30, 2023$11.42B+62.8%
Q2 FY2022Jun 30, 2022$10.77B+65.2%
Q2 FY2021Jun 30, 2021$8.22B+31.0%
Q1 FY2021Mar 31, 2021$7.26B+15.0%
Q4 FY2020Dec 31, 2020$7.01B+12.2%
Q3 FY2020Sep 30, 2020$6.52B+6.3%
Q2 FY2020Jun 30, 2020$6.28B+7.8%
Q1 FY2020Mar 31, 2020$6.31B+15.5%
Q4 FY2019Dec 31, 2019$6.25B+8.4%
Q3 FY2019Sep 30, 2019$6.13B+16.4%
Q2 FY2019Jun 30, 2019$5.82B+13.0%
Q1 FY2019Mar 31, 2019$5.47B+9.6%
Q4 FY2018Dec 31, 2018$5.77B+5.1%
Q3 FY2018Sep 30, 2018$5.27B+7.9%
Q2 FY2018Jun 30, 2018$5.16B+4.4%
Q1 FY2018Mar 31, 2018$4.99B+2.9%
Q4 FY2017Dec 31, 2017$5.49B+4.3%
Q3 FY2017Sep 30, 2017$4.88B-2.8%
Q2 FY2017Jun 30, 2017$4.94B-9.7%
Q1 FY2017Mar 31, 2017$4.84B-13.0%
Q4 FY2016Dec 31, 2016$5.26B–
Q3 FY2016Sep 30, 2016$5.03B–
Q2 FY2016Jun 30, 2016$5.47B–
Q1 FY2016Mar 31, 2016$5.57B–

More AstraZeneca figures

See a number that looks wrong?